PURPOSE: We determined the association between novel and acid-labile skin collagen-linked advanced glycation endproducts (AGEs) and the progression of microvascular and neuropathic complications from baseline to near study closeout in the Diabetes Control and Complications Trial (DCCT). METHODS: From a skin biopsy obtained near the close of the DCCT, proteolytic collagen digests were analyzed by liquid chromatography/mass spectrometry (LC/MS/MS) for glucosepane (GSPNE), glyoxal and methylglyoxal hydroimidazolones (G-H1 and MG-H1) and the glycation product fructose-lysine (FL) using isotope dilution method. RESULTS: GSPNE and MG-H1 correlated with age and diabetes duration (P<0.02), while GSPNE and FL correlated with the history of glycemia expressed as mean A1c (P≤0.003). Age and duration-adjusted GSPNE and FL levels were lower in intensive (INT) vs. conventional (CONV) treatment subjects in the primary prevention DCCT cohort (P<0.0001), and FL was lower in INT in the secondary intervention cohort (P<0.0001). GSPNE was associated with increased incidence of retinopathy progression (odds ratio (OR) / unit increase in GSPNE: 2.5 for 3 step progression on the ETDRS scale, P=0.003) and sustained≥3 microaneurysms (MA) (OR=4.8, P<0.0001) from DCCT baseline up to the time of the biopsy, and prevalence of microalbuminuria or AER>40mg/24h (OR=5.3, P<0.0001), and confirmed clinical neuropathy (OR=3.4, P=0.015) at the time of the biopsy. GSPNE adjusted for mean A1c remained significant for ≥3 MA (P=0.0252) and AER (P=0.0006). The strong association of complications with A1c was reduced or eliminated when adjusted for GSPNE. CONCLUSIONS: Glucosepane is a novel AGE marker of diabetic complications that is robustly associated with nephropathic, retinopathic and neuropathic outcomes despite adjustment for A1c, suggesting that it could be one mediator of these complications with possible diagnostic implications.
PURPOSE: We determined the association between novel and acid-labile skin collagen-linked advanced glycation endproducts (AGEs) and the progression of microvascular and neuropathic complications from baseline to near study closeout in the Diabetes Control and Complications Trial (DCCT). METHODS: From a skin biopsy obtained near the close of the DCCT, proteolytic collagen digests were analyzed by liquid chromatography/mass spectrometry (LC/MS/MS) for glucosepane (GSPNE), glyoxal and methylglyoxal hydroimidazolones (G-H1 and MG-H1) and the glycation product fructose-lysine (FL) using isotope dilution method. RESULTS: GSPNE and MG-H1 correlated with age and diabetes duration (P<0.02), while GSPNE and FL correlated with the history of glycemia expressed as mean A1c (P≤0.003). Age and duration-adjusted GSPNE and FL levels were lower in intensive (INT) vs. conventional (CONV) treatment subjects in the primary prevention DCCT cohort (P<0.0001), and FL was lower in INT in the secondary intervention cohort (P<0.0001). GSPNE was associated with increased incidence of retinopathy progression (odds ratio (OR) / unit increase in GSPNE: 2.5 for 3 step progression on the ETDRS scale, P=0.003) and sustained≥3 microaneurysms (MA) (OR=4.8, P<0.0001) from DCCT baseline up to the time of the biopsy, and prevalence of microalbuminuria or AER>40mg/24h (OR=5.3, P<0.0001), and confirmed clinical neuropathy (OR=3.4, P=0.015) at the time of the biopsy. GSPNE adjusted for mean A1c remained significant for ≥3 MA (P=0.0252) and AER (P=0.0006). The strong association of complications with A1c was reduced or eliminated when adjusted for GSPNE. CONCLUSIONS: Glucosepane is a novel AGE marker of diabetic complications that is robustly associated with nephropathic, retinopathic and neuropathic outcomes despite adjustment for A1c, suggesting that it could be one mediator of these complications with possible diagnostic implications.
Authors: Douwe J Mulder; Tara Van De Water; Helen L Lutgers; Reindert Graaff; Rijk O Gans; Felix Zijlstra; Andries J Smit Journal: Diabetes Technol Ther Date: 2006-10 Impact factor: 6.118
Authors: Y Yu; S R Thorpe; A J Jenkins; J N Shaw; M A Sochaski; D McGee; C E Aston; T J Orchard; N Silvers; Y G Peng; J A McKnight; J W Baynes; T J Lyons Journal: Diabetologia Date: 2006-08-29 Impact factor: 10.122
Authors: Neil H White; Wanjie Sun; Patricia A Cleary; William V Tamborlane; Ronald P Danis; Dean P Hainsworth; Matthew D Davis Journal: Diabetes Date: 2010-02-11 Impact factor: 9.461
Authors: Esther G Gerrits; Helen L Lutgers; Nanne Kleefstra; Reindert Graaff; Klaas H Groenier; Andries J Smit; Rijk O Gans; Henk J Bilo Journal: Diabetes Care Date: 2007-11-26 Impact factor: 19.112
Authors: Xingjun Fan; Jianye Zhang; Mathilde Theves; Christopher Strauch; Ina Nemet; Xiaoqin Liu; Juan Qian; Frank J Giblin; Vincent M Monnier Journal: J Biol Chem Date: 2009-10-23 Impact factor: 5.157
Authors: Ashay D Bhatwadekar; Josephine V Glenn; Gang Li; Tim M Curtis; Tom A Gardiner; Alan W Stitt Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Johan Wadén; Carol Forsblom; Lena M Thorn; Daniel Gordin; Markku Saraheimo; Per-Henrik Groop Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461
Authors: Naila Rabbani; Madhu Varma Chittari; Charles W Bodmer; Daniel Zehnder; Antonio Ceriello; Paul J Thornalley Journal: Diabetes Date: 2010-01-12 Impact factor: 9.461
Authors: Lloyd Paul Aiello; Wanjie Sun; Arup Das; Sapna Gangaputra; Szilard Kiss; Ronald Klein; Patricia A Cleary; John M Lachin; David M Nathan Journal: N Engl J Med Date: 2015-04-30 Impact factor: 91.245
Authors: Rudolf Flückiger; Enzo Cocuzzi; Ram H Nagaraj; Menachem Shoham; Timothy S Kern; M Edward Medof Journal: Mol Immunol Date: 2017-09-05 Impact factor: 4.407
Authors: Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Orestis G Andriotis; Kareem Elsayad; David E Smart; Mathis Nalbach; Donna E Davies; Philipp J Thurner Journal: Biomed Opt Express Date: 2019-03-14 Impact factor: 3.732
Authors: Christopher A Rock; Samuel Keeney; Andrey Zakharchenko; Hajime Takano; David A Spiegel; Abba M Krieger; Giovanni Ferrari; Robert J Levy Journal: Acta Biomater Date: 2021-01-11 Impact factor: 8.947
Authors: Vincent M Monnier; Wanjie Sun; Xiaoyu Gao; David R Sell; Patricia A Cleary; John M Lachin; Saul Genuth Journal: Cardiovasc Diabetol Date: 2015-09-05 Impact factor: 9.951